ALT:? IPD

Marta Avinent-Pérez1, Frank Westermann2, Samuel Navarro3

  • 1Department of Pathology, Medical School, University of Valencia, 46010 Valencia, Spain; Neuroblastoma Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Neoplasia (New York, N.Y.)
|December 29, 2024
PubMed
概括

带有替代端粒延长 (ALT) 的神经母细胞瘤患者的生存率较差. 将端粒维持机制 (TMM) 纳入风险分类可以改善高风险神经母细胞瘤的治疗.